Eliquis, Vyndaqel, Ibrance, Inlyta, Xtandi drove 12% op growth in Biopharm biz (the biz that remains after Upjohn transaction closes in 2H20). Biopharm helped by 15% op growth in emerging markets &amp; 25% op growth in onco. Headwinds/tailwinds. Overall 1Q/1Q revs down 8%. $PFE